Polo-like kinases in AML

Expert Opinion on Investigational Drugs

Volumn 21, Issue 8, 2012, Pages 1069-1074

  Berg, Tobias ^a   Bug, Gesine ^a   Ottmann, Oliver G ^a   Strebhardt, Klaus ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

AML; cell cycle; polo like kinase; targeted therapy

Indexed keywords

ANTHRACYCLINE; ARSENIC TRIOXIDE; AURORA KINASE INHIBITOR; CD135 ANTIGEN; CORE BINDING FACTOR; CYCLIN B1; CYTARABINE; DAUNORUBICIN; DNA METHYLTRANSFERASE INHIBITOR; ETOPOSIDE; FLT3 LIGAND; JANUS KINASE 2 INHIBITOR; MICRORNA 126; NMS 937; POLO LIKE KINASE 1; POLO LIKE KINASE 2; POLO LIKE KINASE 3; POLO LIKE KINASE INHIBITOR; RETINOIC ACID; SORAFENIB; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER PATIENT; CELL CYCLE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CELL PROLIFERATION; CELL STRAIN U937; CHROMOSOME 5; CHROMOSOME LOSS; DOWN REGULATION; DRUG EFFICACY; EPIGENETICS; GENE EXPRESSION; HEMATOPOIETIC STEM CELL; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LEUKEMOGENESIS; LOW DRUG DOSE; M PHASE CELL CYCLE CHECKPOINT; METASTASIS; MUCOSA INFLAMMATION; MYELODYSPLASTIC SYNDROME; NATIONAL HEALTH ORGANIZATION; ONCOGENE; PROMYELOCYTIC LEUKEMIA; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REVIEW; SOLID TUMOR; TUMOR SUPPRESSOR GENE;

ANIMALS; CELL CYCLE PROTEINS; DRUG DISCOVERY; GENES, TUMOR SUPPRESSOR; HUMANS; LEUKEMIA, MYELOID, ACUTE; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS;

EID: 84863680799     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2012.691163     Document Type: Review

References (50)

1. Gupta V, Tallman MS, Weisdorf DJ. Allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia: myths, controversies, and unknowns. Blood 2011;117(8):2307-18
2. Tallman MS, Andersen JW, Schiffer CA, et al. All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med 1997;337(15):1021-8 (Pubitemid 27430519)
3. Small D. FLT3 mutations: biology and treatment. Hematology Am Soc Hematol Educ Program 2006;178-84
4. Bug G, Schlenk RF, Muller-Tidow C, et al. Phase I/II study of BI 6727 (volasertib), an intravenous polo-like kinase-1 (Plk1) inhibitor, in patients with acute myeloid leukemia (AML): results of the dose finding for BI 6727 in combination with low-dose cytarabine. Blood 2010;116(21):abstract 3316
5. Serve H, Wagner R, Sauerland C, et al. Sorafenib in combination with standard induction and consolidation therapy in elderly AML patients: results from a randomized, placebo-controlled phase II trial. Blood 2010;116(21): abstract 333
6. Muller-Tidow C, Ji P, Diederichs S, et al. The cyclin A1-CDK2 complex regulates DNA double-strand break repair. Mol Cell Biol 2004;24(20):8917-28 (Pubitemid 39313897)
7. Wang Y, Krivtsov AV, Sinha AU, et al. The Wnt/beta-catenin pathway is required for the development of leukemia stem cells in AML. Science 2010;327(5973):1650-3
8. Claus R, Lubbert M. Epigenetic targets in hematopoietic malignancies. Oncogene 2003;22(42):6489-96 (Pubitemid 37372329)
9. Strebhardt K, Ullrich A. Paul Ehrlich's magic bullet concept: 100 years of progress. Nat Rev Cancer 2008;8(6):473-80 (Pubitemid 351752547)
10. Barr FA, Sillje HH, Nigg EA. Polo-like kinases and the orchestration of cell division. Nat Rev Mol Cell Biol 2004;5(6):429-40 (Pubitemid 38745493)
11. Archambault V, Glover DM. Polo-like kinases: conservation and divergence in their functions and regulation. Nat Rev Mol Cell Biol 2009;10(4):265-75
12. Strebhardt K. Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy. Nat Rev Drug Discov 2010;9(8):643-60
13. Holtrich U, Wolf G, Brauninger A, et al. Induction and down-regulation of PLK, a human serine/threonine kinase expressed in proliferating cells and tumors. Proc Natl Acad Sci USA 1994;91(5):1736-40 (Pubitemid 24080280)
14. Yuan J, Horlin A, Hock B, et al. Polo-like kinase, a novel marker for cellular proliferation. Am J Pathol 1997;150(4):1165-72 (Pubitemid 27152634)
15. Wolf G, Elez R, Doermer A, et al. Prognostic significance of polo-like kinase (PLK) expression in non-small cell lung cancer. Oncogene 1997;14(5):543-9 (Pubitemid 27090956)
16. Knecht R, Oberhauser C, Strebhardt K. PLK (polo-like kinase), a new prognostic marker for oropharyngeal carcinomas. Int J Cancer 2000;89(6):535-6
17. Wolf G, Hildenbrand R, Schwar C, et al. Polo-like kinase: a novel marker of proliferation: correlation with estrogen-receptor expression in human breast cancer. Pathol Res Pract 2000;196(11):753-9
18. Strebhardt K, Ullrich A. Targeting polo-like kinase 1 for cancer therapy. Nat Rev Cancer 2006;6(4):321-30
19. Knecht R, Elez R, Oechler M, et al. Prognostic significance of polo-like kinase (PLK) expression in squamous cell carcinomas of the head and neck. Cancer Research 1999;59(12):2794-7 (Pubitemid 29283110)
20. Strebhardt K, Kneisel L, Linhart C, et al. Prognostic value of polo-like kinase expression in melanomas. JAMA 2000;283(4):479-80 (Pubitemid 30062860)
21. Kneisel L, Strebhardt K, Bernd A, et al. Expression of polo-like kinase (PLK1) in thin melanomas: a novel marker of metastatic disease. J Cutan Pathol 2002;29(6):354-8
22. Luo J, Emanuele MJ, Li D, et al. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the ras oncogene. Cell 2009;137(5):835-48
23. Raab M, Kappel S, Kramer A, et al. Toxicity modelling of Plk1-targeted therapies in genetically engineered mice and cultured primary mammalian cells. Nat Commun 2011;2:395
24. Liu X, Lei M, Erikson RL. Normal cells, but not cancer cells, survive severe Plk1 depletion. Mol Cell Biol 2006;26(6):2093-108 (Pubitemid 43346913)
25. Spankuch-Schmitt B, Bereiter-Hahn J, Kaufmann M, Strebhardt K. Effect of RNA silencing of polo-like kinase-1 (PLK1) on apoptosis and spindle formation in human cancer cells. J Natl Cancer Institute 2002;94(24):1863-77 (Pubitemid 36104631)
26. Spankuch-Schmitt B, Wolf G, Solbach C, et al. Downregulation of human polo-like kinase activity by antisense oligonucleotides induces growth inhibition in cancer cells. Oncogene 2002;21(20):3162-71 (Pubitemid 34548087)
27. Liu X, Erikson RL. Polo-like kinase (Plk) 1 depletion induces apoptosis in cancer cells. Proc Natl Acad Sci USA 2003;100(10):5789-94 (Pubitemid 36576886)
28. Spankuch B, Matthess Y, Knecht R, et al. Cancer inhibition in nude mice after systemic application of U6 promoter-driven short hairpin RNAs against PLK1. J Natl Cancer Institute 2004;96(11):862-72 (Pubitemid 38807607)
29. Spankuch B, Heim S, Kurunci-Csacsko E, et al. Down-regulation of Polo-like kinase 1 elevates drug sensitivity of breast cancer cells in vitro and in vivo. Cancer Res 2006;66(11):5836-46 (Pubitemid 43927138)
30. Steegmaier M, Hoffmann M, Baum A, et al. BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo. Current Biol CB 2007;17(4):316-22 (Pubitemid 46241881)
31. Lenart P, Petronczki M, Steegmaier M, et al. The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 1. Current Biol CB 2007;17(4):304-15
32. Rudolph D, Steegmaier M, Hoffmann M, et al. BI 6727, a polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity. Clin Cancer Res 2009;15(9):3094-102
33. Ikezoe T, Yang J, Nishioka C, et al. A novel treatment strategy targeting polo-like kinase 1 in hematological malignancies. Leukemia 2009;23(9):1564-76
34. Renner AG, Dos Santos C, Recher C, et al. Polo-like kinase 1 is overexpressed in acute myeloid leukemia and its inhibition preferentially targets theproliferation of leukemic cells. Blood 2009;114(3):659-62
35. Syed N, Smith P, Sullivan A, et al. Transcriptional silencing of Polo-like kinase 2 (SNK/PLK2) is a frequent event in B-cell malignancies. Blood 2006;107(1):250-6 (Pubitemid 43053549)
36. Benetatos L, Dasoula A, Hatzimichael E, et al. Polo-like kinase 2 (SNK/PLK2) is a novel epigenetically regulated gene in acute myeloid leukemia and myelodysplastic syndromes: genetic and epigenetic interactions. Ann Hematol 2011;90(9):1037-45
37. Li Z, Lu J, Sun M, et al. Distinct microRNA expression profiles in acute myeloid leukemia with common translocations. Proc Natl Acad Sci USA 2008;105(40):15535-40
38. Yuan J, Sanhaji M, Kramer A, et al. Polo-box domain inhibitor poloxin activates the spindle assembly checkpoint and inhibits tumor growth in vivo. Am J Pathol 2011;179(4):2091-9
39. Lee KS, Song S, Erikson RL. The polo-box-dependent induction of ectopic septal structures by a mammalian polo kinase, plk, in Saccharomyces cerevisiae. Proc Natl Acad Sci USA 1999;96(25):14360-5 (Pubitemid 30000655)
40. Reindl W, Yuan J, Kramer A, et al. Inhibition of polo-like kinase 1 by blocking polo-box domain-dependent protein-protein interactions. Chem Biol 2008;15(5):459-66 (Pubitemid 351645109)
41. Reindl W, Yuan J, Kramer A, et al. A pan-specific inhibitor of the polo-box domains of polo-like kinases arrests cancer cells in mitosis. ChemBioChem 2009;10(7):1145-8
42. Watanabe N, Sekine T, Takagi M, et al. Deficiency in chromosome congression by the inhibition of Plk1 polo box domain-dependent recognition. J Biol Chem 2009;284(4):2344-53
43. Valsasina B, Beria I, Alli C, et al. NMS-P937, an orally available, specific, small molecule Polo-Like Kinase 1 inhibitor with antitumor activity in solid and haematological malignancies. Mol Cancer Ther 2012;11(4):1006-16
44. Bug G, Muller-Tidow C, Schlenk RF, et al. Phase I/II study of volasertib (BI 6727), an intravenous polo-like kinase (Plk) inhibitor, in patients with acute myeloid leukemia (AML): updated results of the dose finding phase i part for volasertib in combination with low-dose cytarabine (LD-Ara-C) and as monotherapy in relapsed/refractory AML. Blood 2011;118(21):abstract 1549
45. Lucena-Araujo AR, de Oliveira FM, Leite-Cueva SD, et al. High expression of AURKA and AURKB is associated with unfavorable cytogenetic abnormalities and high white blood cell count in patients with acute myeloid leukemia. Leuk Res 2011;35(2):260-4
46. Boss DS, Beijnen JH, Schellens JH. Clinical experience with aurora kinase inhibitors: a review. Oncologist 2009;14(8):780-93
47. Lowenberg B, Muus P, Ossenkoppele G, et al. Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia. Blood 2011;118(23):6030-6
48. Didier C, Cavelier C, Quaranta M, et al. Evaluation of polo-like kinase 1 inhibition on the G2/M checkpoint in acute myelocytic leukaemia. Eur J Pharmacol 2008;591(1-3):102-5
49. Cucchi U, Gianellini LM, De Ponti A, et al. Phosphorylation of TCTP as a marker for polo-like kinase-1 activity in vivo. Anticancer Res 2010;30(12):4973-85
50. Park JE, Li L, Park J, et al. Direct quantification of polo-like kinase 1 activity in cells and tissues using a highly sensitive and specific ELISA assay. Proc Natl Acad Sci USA 2009;106(6):1725-30